

Royal Brisbane & Women's Hospital Human Research Ethics Committee Metro North Hospital and Health Service

Enquiries to: Ann-Maree Gordon

Coordinator

Telephone: 07 3646 5490

File Ref: HREC/2018/QRBW/46295
Email: RBWH-Ethics@health.qld.gov.au

Ms Nicole Marsh Nursing and Midwifery Research Centre Royal Brisbane & Women's Hospital Herston Old 4029

Dear Ms Marsh,

Re: Ref Nº: HREC/2018/QRBW/46295: Managing Intravenous Devices among patients with Limited vascular access or prolonged therapy: InvestigatiNg the Efficacy of midline catheters

Thank you for submitting the above research project for single ethical review. This project was considered by the Royal Brisbane & Women's Hospital Human Research Ethics Committee (RBWH HREC) (EC00172) at its meeting held on 12 November 2018. The research project meets the requirements of the National Health and Medical Research Council's (NHMRC) *National Statement on Ethical Conduct in Human Research* (2007).

I am pleased to advise that the RBWH Human Research Ethics Committee has granted ethical approval of this research project.

The nominated participating site for this project is:

• Royal Brisbane & Women's Hospital

This letter constitutes ethical approval only. This project cannot proceed until separate research governance authorisation has been obtained from the CEO or Delegate of the Royal Brisbane & Women's Hospital under whose auspices the research will be conducted.

The approved documents include:

Document	Version	Date
Cover Letter		29 October 2018
HREA	Oct ver 1	26 October 2018
Participant Revocation of Consent Form	1.0	26 September 2018
Data Collection Sheet (REDCap)		

Document Version Date The PowerWand Information Sheet TGA eBS Record Summary Grant approval from the Australian College of Nursing 18 July 2018 (ACN) Letter of Support from Professor Wendy Moyle, Program Director, Healthcare Practice & Survivorship Program, 13 April 2018 Menzies Health Institute of Queensland, Griffith University Confirmation of Protection – Professional Liability Protection 01 November 2017 for the period 01.11.2017 to 31.10.2018 Confirmation of Protection – General and Products Liability 01 November 2017 Protection for the period 01.11.2017 to 31.10.2018 Curriculum Vitae of Nicole Marsh 22 November 2018 Response to request for further information MIDLINE Trial Protocol 1.1 22 November 2018 1.1 20 November 2018 Participant Information Sheet Participant Consent Form 1.1 20 November 2018 1.1 Substitute Decision Maker Information Sheet 20 November 2018 1.1 20 November 2018 Substitute Decision Maker Consent Form Email of support from Dr Krispin Hajkowicz, Infectious 22 November 2018 Diseases, RBWH Response to request for further information 05 December 2018 03 December 2018 Staff Information Sheet 1.0

2

Approval of this project from the RBWH HREC is valid from **05.12.2018** to **05.12.2021** subject to the following conditions being met:

- The Coordinating Principal Investigator will immediately report anything that might warrant review of ethical approval of the project.
- The Coordinating Principal Investigator will notify the RBWH HREC of any event that
 requires a modification to the protocol or other project documents and submit any
 required amendments in accordance with the instructions provided by the HREC. These
 instructions can be found at https://www.health.qld.gov.au/metronorth/research/ethics-governance/hrec-approval/default.asp.
- The Coordinating Principal Investigator will submit any necessary reports related to the safety of research participants in accordance with the RBWH HREC policy and procedures. These instructions can be found at https://www.health.qld.gov.au/metronorth/research/ethics-governance/post-approval-reporting/default.asp.

· ------

3

- In accordance with Section 3.3.22 (b) of the National Statement the Coordinating Principal Investigator will report to the RBWH HREC annually in the specified format, the first report being due on **05.12.2019** and a final report is to be submitted on completion of the study. These instructions can be found at https://www.health.qld.gov.au/metronorth/research/ethics-governance/post-approval-reporting/default.asp.
- The Coordinating Principal Investigator will notify the RBWH HREC if the project is discontinued before the expected completion date, with reasons provided.
- The Coordinating Principal Investigator will notify the RBWH HREC of any plan to extend
 the duration of the project past the approval period listed above and will submit any
 associated required documentation. Instructions for obtaining an extension of approval
 can be found at https://www.health.qld.gov.au/metronorth/research/ethics-governance/hrec-approval/default.asp.
- The Coordinating Principal Investigator will notify the RBWH HREC of his or her inability to continue as Coordinating Principal Investigator including the name of and contact information for a replacement.
- A copy of this ethical approval letter together with completed Site Specific Assessment (SSA) and any other requirements must be submitted by the Coordinating Principal Investigator to the Research Governance Office at the Royal Brisbane & Women's Hospital in a timely manner to enable the institution to authorise the commencement of the project at its site.
- Should you have any queries about the RBWH HREC's consideration of your project
 please contact the HREC Coordinator on 07 3646 5490. The RBWH HREC's Terms of
 Reference, Standard Operating Procedures, membership and standard forms are available
 from https://www.health.qld.gov.au/metronorth/research/ethics-governance/hrec-approval/membership/default.asp.

The RBWH HREC wishes you every success in your research.

Yours sincerely,

Dr Gordon McGurk

Gordan & Till Gurh

Chairperson RBWH Human Research Ethics Committee

Metro North Hospital and Health Service

05.12.2018

This HREC is constituted and operates in accordance with the National Health and Medical Research Council's (NHMRC) *National Statement on Ethical Conduct in Human Research* (2007). The processes used by this HREC to review research proposals have been certified by the National Health and Medical Research Council.